New tetracycline for drug-resistant bacterial infections
Part of Infections clinical trials.
This trial tests a new tetracycline antibiotic (neotetracycline) for treating infections caused by drug-resistant Gram-negative bacteria. It aims to see how well the drug works and what side effects it may have.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a lab-confirmed infection with drug-resistant Gram-negative bacteria.
- You must be willing to take the new tetracycline drug for at least 72 hours (3 days).
- You must be 18 years old or older.
- You cannot have an advanced cancer, severe immune deficiency or mental illness, severe liver or kidney problems, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether inhaling an antibiotic called tobramycin can prevent a serious lung infection in patients who need a breathing tube. It may help people at higher risk for difficult-to-treat infections.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
Hear when a new Clinical Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.